High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients

Table 4

Multivariate association of 24-week OS with serum miR-122 concentration according to HBV-DNA or HBeAg status.

	24-week OS^a (n)	Total (n)	Univariate HR (95%CI)^a	Multivariate HR (95%CI)^a,b
Positive HBV-DNA^c
miR122_L group	54	77	Reference	Reference
miR122_H group	57	73	1.11 (0.92∼1.35)	1.12 (0.93∼1.35)
Negative HBV-DNA
miR122_L group	149	217	Reference	Reference
miR122_H group	184	221	1.21 (1.09∼1.35)	1.22 (1.09∼1.36)
Positive HBeAg
miR122_L group	48	68	Reference	Reference
miR122_H group	41	59	0.98 (0.78∼1.24)	0.99 (0.78∼1.25)
Negative HBeAg
miR122_L group	155	226	Reference	Reference
miR122_H group	200	235	1.24 (1.12∼1.38)	1.25 (1.13∼1.39)

^aOS: overall survival; HR: hazard ratio; CI: confidence interval. ^bThe multivariate COX model was adjusted by gender, age, annual income, HBeAg, HBV-DNA, serum albumin, serum total bilirubin, serum fetoprotein, ECOG score, maximum diameter of tumor, number of tumors, extent of tumor, portal vein invasion, and hepatic vein invasion. ^cPositive HBV-DNA was defined as HBV-DNA ≥ 10³ copies/ml.